LIBRETTO-432 Trial at ASCO 2026 Plenary Session: Adjuvant Selpercatinib in RET Fusion-Positive NSCLC
oncodaily - LIBRETTO-432 Trial was presented during ASCO 2026 by Jonathan W. Goldman, MD, as a global, multicenter, phase 3, double-blind, randomized, placebo-controlled study evaluating adjuvant selpercatinib in patients with early-stage RET […]
AI Summary: At ASCO26 plenary, LIBRETTO‑432 data show adjuvant selpercatinib markedly prolongs event‑free survival and slashes recurrence risk for patients with stage II–IIIA RET fusion–positive non‑small cell lung cancer after curative treatment. The findings support a new standard for this rare genetic subgroup and press the case for routine genomic testing.
Related Stories
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 8 hrs
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 2 months
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 6 wks
DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 5 wks
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 7 wks
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days
Long‑term Botensilimab+Balstilimab data show durable responses in MSS CRC / 13 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Food Safety, Health IT, Medicaid, Pediatric Oncology and look for the RSS link.
StackHealth Time Machine